Authors:
Address: Department of Gastroenterology, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. jinkans@med.juntendo.ac.jp
Journal:

Publication:

abstract

BACKGROUND:

The aim of the present study was to examine the potential Efficacy of camostat mesilate, a protease inhibitor, against dyspepsia associated with non-alcoholic mild pancreatic disease.

METHODS:

Patients with upper abdominal pain suggesting pancreatic disease (persistent over hours, pain aggravated by ingestion of food, epigastric pain radiating to the back), without a history of alcohol consumption and who exhibited no abnormalities regarding serum amylase and lipase, ultrasonography, CT and upper gastrointestinal endoscopy, were prescribed 200 mg camostat mesilate three times daily for 2 weeks. The patients were subjected to endoscopic ultrasonography (EUS) while under treatment and were distributed into those who had 4 or more suggestive findings of chronic pancreatitis (suspected pancreatic disease group), 2 or 3 (equivalent group) and those with 1 or no findings (control group). Symptom severity was recorded before and after treatment using a 10-cm visual analog scale (VAS).

RESULTS:

Among 95 patients, 40 were in the suspected pancreatic disease group, 30 were in the equivalent group and 25 served as controls. A significant intra- and intergroup improvement of symptoms was observed not only in the suspected pancreatic disease group but also in the equivalent group.

CONCLUSIONS:

Camostat mesilate may serve as a therapeutic agent for patients with dyspepsia associated with mild pancreatic disease, who do not habitually drink alcohol.

Related Articles
Efficacy of camostat mesilate compared with famotidine for treatment of functional dyspepsia: is camostat mesilate effective?
J Gastroenterol Hepatol. 2006
Efficacy of camostat mesilate compared with famotidine for treatment of functional dyspepsia: is camostat mesilate effective?
Ashizawa N, Hashimoto T, Miyake T, Shizuku T, Imaoka T, Kinoshita Y. J Gastroenterol Hepatol. 2006 Apr; 21(4):767-71.
The proteinase inhibitor camostat mesilate suppresses pancreatic pain in rodents.
Life Sci. 2007
The proteinase inhibitor camostat mesilate suppresses pancreatic pain in rodents.
Ishikura H, Nishimura S, Matsunami M, Tsujiuchi T, Ishiki T, Sekiguchi F, Naruse M, Nakatani T, Kamanaka Y, Kawabata A. Life Sci. 2007 May 1; 80(21):1999-2004. Epub 2007 Mar 12.
EUS to detect evidence of pancreatic disease in patients with persistent or nonspecific dyspepsia.
Gastrointest Endosc. 2000
EUS to detect evidence of pancreatic disease in patients with persistent or nonspecific dyspepsia.
Sahai AV, Mishra G, Penman ID, Williams D, Wallace MB, Hadzijahic N, Pearson A, Vanvelse A, Hoffman BJ, Hawes RH. Gastrointest Endosc. 2000 Aug; 52(2):153-9.
Continuous regional arterial infusion therapy with gabexate mesilate for severe acute pancreatitis.
World J Gastroenterol. 2008
Continuous regional arterial infusion therapy with gabexate mesilate for severe acute pancreatitis.
Ino Y, Arita Y, Akashi T, Kimura T, Igarashi H, Oono T, Furukawa M, Kawabe K, Ogoshi K, Ouchi J, et al. World J Gastroenterol. 2008 Nov 7; 14(41):6382-7.
Oral administration of sepimostat mesilate prevents acute alcohol pancreatic injury in rats.
J Pharm Pharmacol. 1999
Oral administration of sepimostat mesilate prevents acute alcohol pancreatic injury in rats.
Yuasa C, Irimura K, Oda M, Fukui K, Oka T. J Pharm Pharmacol. 1999 Jul; 51(7):867-71.

To top • Home

---

Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer • webmaster